Stock Market & Financial Investment News

News Breaks December 14, 2011 05:29 EDT THLD theflyonthewall.com: Threshold Pharma announces clinical trial results of Phase 1 TH-302 study Threshold Pharmaceuticals announced clinical trial results of the Phase 1 study of TH-302 in patients with advanced leukemias conducted at MD Anderson's Cancer Center in Houston, Texas. Thirty-two patients with either acute myelogenous leukemia or acute lymphoblastic leukemia have been enrolled in the trial to date. The starting dose in the trial was 120mg/m2 daily for 5 days of a 21-day cycle and the highest dose investigated in the study was 550 mg/m2. At this dose two patients developed dose limiting mucosal toxicity. The maximum tolerated daily dose of TH-302 was established at 460 mg/m2. Efficacy assessments have demonstrated TH-302 activity in multiple subjects with relapsed/refractory AML and ALL as evidenced by stabilization or reduction of bone marrow and peripheral blast counts. One patient had a complete response with incomplete platelet recovery with resolution of leukemia cutis. A dose expansion with 10 additional evaluable patients is ongoing at the MTD. :theflyonthewall.com News For THLD From The Last 14 Days Check below for free stories on THLD the last two weeks. There is 1 item on the Fly with pertinent information. Sign up for a free trial to see the rest of the stories you've been missing. May 25, 2012 07:36 EDT THLD theflyonthewall.com: Threshold Pharmaceuticals remains undervalued, says Cowen Cowen said Threshold Pharmaceuticals remains undervalued in relation the potential of it's TH-302 drug for pancreatic cancer. The firm noted positive Phasellb results and estimates the sales potential in the U.S. alone at $1.5B+. Shares are Outperform rated. :theflyonthewall.com